Concizumab PKPD Simulator
Indication: Hemophilia
PK/PD simulator for concizumab (Alhemo) in hemophilia. TMDD model with TFPI suppression visualization.
Drug Overview
Clinical Context
- Molecular Target
- TFPI
- Drug Class
- mAb
- Therapeutic Area
- Hematology
- Indication
- Hemophilia
- Route of Administration
- SC
Model Information
- Model Type
- 2-compartment with TMDD
- Category
- PK/PD
- Reference
- Yuan et al. Eur J Pharm Sci 2019;138:105032
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Concizumab allows you to explore concentration-time profiles under different dosing scenarios. The underlying PK/PD model characterizes the pharmacokinetics of this mab following sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Concizumab PK simulator?
This is a free, interactive pharmacokinetic simulator for Concizumab used in Hemophilia. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Concizumab belong to?
Concizumab is classified as a mAb that targets TFPI. It is used in the Hematology therapeutic area.
What route of administration does this model simulate?
This simulator models SC administration of Concizumab. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Xolair (Omalizumab) PK Simulator
Moderate-to-severe allergic asthma
Tremfya (Guselkumab) PK Simulator
Plaque psoriasis
Tecentriq (Atezolizumab) PK Simulator
Non-small cell lung cancer
Stelara (Ustekinumab) PK Simulator
Plaque psoriasis
Skyrizi (Risankizumab) PK Simulator
Plaque psoriasis
Prolia (Denosumab) PK Simulator
Postmenopausal osteoporosis
Ready to Simulate?
Launch the Concizumab simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community